The Dedham Group

What The Dedham Group does

The Dedham Group is a New York-based strategy consulting firm specializing in life sciences market access and commercialization, founded in 2004 and operating as a subsidiary of Norstella. The firm serves pharmaceutical and biotechnology manufacturers across the product lifecycle, with concentrated expertise in oncology and adjacent specialty therapeutics including cell and gene therapy, rare disease, immunology, and cardiovascular, diabetes, and metabolic disease. Services span value and access (clinical pathways strategy, payer access and reimbursement, provider account engagement, distribution strategy, patient support programs) and commercial advisory (corporate strategy, portfolio strategy, forecasting, go-to-market strategy, launch excellence, and new product planning). Engagements are delivered through white-glove, relationship-driven enterprise consulting.

The firm's proprietary technology asset is PULSE Analytics, a decision support platform covering 90+ provider accounts, 9,000+ oncologists, 89 million payer medical lives, 75+ organizations, and 2,000+ key decision makers across 150+ brands per pathway. PULSE modules address clinical pathways, payer quality of access, provider key accounts, key decision makers, net cost recovery, alternative payment models, medical benefit management, distribution analog launch planning, and VA oncology access. Complementing PULSE is a Syndicated Reports product line delivering subscription-based research on IRA/MFP dynamics, biosimilars, VA oncology, oncology benefit managers, whitebagging, 340B restrictions, and cell and gene therapy economics.

The business model combines professional services revenue (consulting engagements with biopharma manufacturers) with subscription recurring revenue from PULSE Analytics and Syndicated Reports. Go-to-market is direct enterprise sales with relationship-based business development; PULSE is also accessible via a self-serve portal at pulse-tools.com. Pricing is quote-based for consulting and not publicly disclosed for PULSE or Syndicated Reports. The firm is privately held under Norstella, with no public filings, and operates from One Pennsylvania Plaza, Suite 2710, New York.

Name

The Dedham Group

Legal name

Caerus US 1, Inc.

Website

https://dedhamgroup.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

The Dedham Group is a New York-based life sciences strategy consulting firm and Norstella subsidiary that advises pharmaceutical and biotech manufacturers on market access, commercialization, and launch excellence, supported by its proprietary PULSE Analytics platform and Syndicated Reports subscription products.

Ownership category

akta.pro rank

Product category

Pharmaceutical Market Access Consulting

NAICS

Management Consulting Services (54161), Administrative Management and General Management Consulting Services (541611)

SIC

Services-Management Consulting Services (8742), Services-Management Services (8741)

akta.pro primary industry

Strategy & Corporate Development Consulting (BPAHACAA)

Keywords

• Pharma market access
• Biotech strategy consulting
• Payer reimbursement strategy
• Oncology market access
• Launch excellence consulting

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Strategy Consulting Services: Professional services revenue model providing consulting engagements to pharmaceutical and biotech manufacturers. Services span market access strategy, commercial advisory, launch excellence, new product planning, corporate strategy, portfolio strategy, forecasting, and business development. Engagements are white-glove, high-touch expert advisory relationships with biopharma clients.
2. PULSE Analytics Subscription: Subscription-based access to PULSE Analytics decision support tools, providing syndicated data and analytics to pharma companies for market access planning and account targeting. Clients include pharmaceutical manufacturers seeking actionable insights on clinical pathways, payer access, provider accounts, and distribution dynamics.
3. Syndicated Reports: Pre-packaged research reports on market access topics including IRA impact, biosimilar dynamics, VA oncology access, specialty carveouts, oncology benefit managers, whitebagging, oncology practice collaboratives, 340B restrictions, and cell & gene therapy economics. Sold as periodic subscription or individual report purchases.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

The Dedham Group is a top-tier strategy consulting firm serving biopharmaceutical manufacturers, providing market access, commercialization, and launch excellence advisory services. Its offerings include custom consulting engagements spanning clinical pathways strategy, payer access and reimbursement, distribution strategy, provider engagement, corporate and portfolio strategy, forecasting, and new product planning, complemented by a proprietary PULSE Analytics decision support platform and subscription-based Syndicated Reports.

Product overview

The Dedham Group is a strategy consulting firm offering two primary product lines: PULSE Analytics (a decision support platform providing data-driven insights across clinical pathways, payer quality of access, provider key accounts, key decision makers, net cost recovery, alternative payment models, medical benefit management, distribution planning, and VA oncology access) and Syndicated Reports (premium research publications covering IRA evolution, biosimilar dynamics, payer ecosystems, oncology practice collaboratives, and cell/gene therapy access topics). These offerings complement the firm's consulting services spanning clinical pathways strategy, patient support programs, distribution strategy, payer access, provider engagement, corporate strategy, portfolio strategy, forecasting, go-to-market strategy, launch excellence, and new product planning.

Differentiator

Problem solved

Functional benefit

Brands

• PULSE Analytics: Decision support tools for market access in oncology and specialty therapeutics, providing data on clinical pathways, payer quality of access, provider key accounts, key decision makers, net cost recovery, alternative payment models, medical benefit management, distribution analog launch planning, and VA oncology access.
• Syndicated Reports

Products and services

• PULSE Analytics
• Syndicated Reports Subscription-based research reports on market access topics including IRA impact, biosimilar dynamics, VA oncology access, specialty carveouts, oncology benefit managers, whitebagging, oncology practice collaboratives, 340B restrictions, and cell & gene therapy economics. Sold as periodic subscriptions or individual report purchases.
• Strategy Consulting Services

Quantifiable outcome

• Over 125 pre-launch projects delivered annually, driving success for emerging products
• +3 more outcomes

Named customers2 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• MMITcoreTechnology or IntegrationMMIT (Managed Markets Insight & Technology) is a sister company within the Norstella family. The Dedham Group collaborated with MMIT to produce the 2024 State of Patient Access industry report, surveying 309 pharma and biotech leaders. MMIT's market access data and analytics capabilities complement Dedham's strategic consulting services, with integrated data assets enhancing Dedham's PULSE Analytics platform and strategic project capabilities.
• TempusminorStrategic or Co-development PartnerTempus is referenced as a leading AI-in-oncology company that embeds its AI engine into EHR systems, surfacing alerts for clinical trial eligibility and treatment opportunities. Dedham discusses Tempus in the context of AI alert fatigue in oncology — noting Tempus's partnership with Stemline Therapeutics where Tempus's AI scans patient records to flag potential candidates for Orserdu. Tempus represents the type of AI/digital health company shaping the oncology landscape that Dedham advises clients on.
• Stemline TherapeuticsminorStrategic or Co-development PartnerStemline Therapeutics partnered with Tempus to use AI scanning of patient records to identify potential candidates for Orserdu (elacestrant), generating real-time alerts within physician EHR workflows. This partnership is discussed in Dedham's analysis of AI alert fatigue in oncology as an example of the growing integration of AI platforms into oncology care delivery.
• AssistRxminorStrategic or Co-development PartnerThe Dedham Group participated as a panelist in AssistRx's webinar 'Ahead of the Curve: Considerations for Your 2025 Patient Support Program' to discuss IRA-driven changes to patient support programs. This represents a thought leadership and GTM partnership where Dedham contributes expertise on IRA and patient access topics alongside AssistRx's patient support technology platform.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• IQVIA: Global leader in life sciences consulting and data analytics, with deep market access, commercial strategy, and real-world data offerings serving the same biopharma manufacturers as The Dedham Group. Both compete for pre-launch and market access engagements with proprietary data assets.
• ZS Associates: Global management consulting and technology firm focused on pharmaceutical sales, marketing, and market access strategy. ZS's data-driven approach to pharma commercialization directly overlaps with Dedham's PULSE Analytics and advisory offerings for biopharma manufacturers.
• Trinity Life Sciences: Specialist life sciences strategy consulting firm offering commercial strategy, market access, and evidence-based analytics for biopharma. Provides comparable strategy and decision support services to the same pharmaceutical and biotech client base as The Dedham Group.
• Lumanity: Life sciences consulting firm offering strategic advisory, market access, medical affairs, and HEOR services to biopharma manufacturers. Directly comparable in focus areas (market access, launch excellence, oncology) and client profile to The Dedham Group.
• Simon-Kucher & Partners: Global consulting firm specializing in pricing, market access, and commercial strategy for life sciences and other industries. Competes with Dedham on pharma pricing, access strategy, and launch planning engagements.
• Charles River Associates: Global consulting firm with a Life Sciences practice providing strategy, market access, and commercial advisory services to pharma and biotech manufacturers. Overlapping client base and engagement types make it a relevant comparable to The Dedham Group.

Broad incumbents

• McKinsey & Company (Pharma Practice): Global generalist management consultancy with a large Pharmaceuticals & Medical Products practice serving biopharma manufacturers on corporate strategy, market access, and commercial transformation. Competes with Dedham on enterprise pharma strategy mandates but with a much broader portfolio of services.
• Boston Consulting Group (Pharma Practice): Global management consultancy with a strong life sciences practice covering commercial strategy, market access, and launch excellence. Competes for top-tier biopharma strategy engagements alongside Dedham but operates across many industries.

Others

• MMIT (Managed Markets Insight & Technology): Sister company within the Norstella family that focuses on payer data and market access analytics. While not a direct competitor (it is part of the same parent), MMIT operates in adjacent market access data territory and collaborates with Dedham on integrated offerings like the State of Patient Access report.
• Citeline: Norstella-owned clinical and commercial intelligence platform serving pharma R&D and commercial teams. As a sibling brand under Norstella, Citeline provides complementary data assets that enhance Dedham's PULSE Analytics and strategic advisory offerings.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/thededhamgroup
• Xx.com/TheDedhamGroup
• Facebookfacebook.com/The-Dedham-Group-219368015254046

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Dedham Group